COMP <GO>
BGM vs NBP // FREE CASH FLOW YIELD
BGM Group Ltd. (Class A) (NASDAQ) VS. NovaBridge Biosciences (NASDAQ) • 15-METRIC TALLY: BGM 3
— NBP 0
■ METRIC PARITY
LAST: $9.54 (0.00%) • MKT CAP: $127.4M
fcf-yield
-3.09%
LAST: $1.01 (-5.61%) • MKT CAP: $123.5M
fcf-yield
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BGM VS. NBP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BGM | NBP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 16.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -3.09% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -33.20% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -52.60% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 51.10% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 1/9 | +1.00 | BGM | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.6 | 30.1 | +26.50 | BGM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $127.4M | $123.5M | $3.9M | BGM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BGM REV | NBP REV | BGM GROSS % | NBP GROSS % | BGM FCF | NBP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $37.9M | $264.0M | 16.6% | — | -$3.9M | — |
| FY 2024 | $25.1M | $144.0M | 16.4% | — | $304.1K | — |
| FY 2023 | $46.5M | $632.0K | — | — | $312.2K | -$183.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BGM // BETA —
NBP // BETA —